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httpcense.Abstract Background: According to the results of a number of phase 3 randomized studies,
sorafenib is the only approved systemic therapy for advanced HCC; however the issue of high eco-
nomic cost remains challenging; thus we have conducted this retrospective analysis of our HCC
patients treated with sorafenib.
Methods: HCC Shams University Hospitals, in the period between 2010 and 2012 were reviewed.
Eligible patients were those who had received sorafenib for advanced HCC not eligible for or pro-
gressed after surgery or locoregional therapy. We investigated the impact of baseline clinicopatho-
logical factors (age, gender, child status, performance score, BCLC tumor stage, cause of chronic
liver disease, median baseline alpha fetoprotein level and previous treatment received for HCC)
on overall survival (OS) in an adjusted Cox regression model.
Results: 41 patients were included in the analysis fulﬁlling the inclusion criteria. At a median follow
up period of 13 months, the median PFS for the whole group was 4 months; the median OS for the
whole group is 6.25 months. Multivariate analysis identiﬁed three baseline characteristics that werercinoma; NCI-CTC, national
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10 O. Abdel-Rahman et al.prognostic indicators for overall survival: ECOG performance status (median OS for ECOG
1 = 7.01 months and for ECOG 2 = 3.03 months), Child–Pugh status (median OS for child
A = 12.04 months and for child B = 5.23 months), and median baseline levels of alpha-fetoprotein.
Conclusions: In limited resource countries like Egypt, we suggest that the use of sorafenib for the
treatment of advanced HCC cases should be restricted to a highly selected subgroup of patients with
good performance and child A.
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Hepatocellular carcinoma (HCC) is the most common liver
neoplasm and the ﬁfth most common cancer worldwide [1].
Sorafenib – a multikinase inhibitor – is the ﬁrst agent which
demonstrated survival beneﬁts in patients with unresectable
advanced HCC. This signiﬁcant progress in the treatment of
HCC was based upon 2 landmark phase 3 studies (SHARP
study in the western population and Asian paciﬁc study in
the Asian paciﬁc population) that has been reconﬁrmed in a
number of phase 2 and 3 studies in different parts of the world
[2,3]. However when applied to the practice in Egypt, the vast
majority of patients enrolled in these landmark studies were in
good performance status (PS) 0 or 1 and had a compensated
liver function classiﬁed as Child Pugh A (CP-A). Conversely,
in real practice in Egypt the majority of patients with advanced
HCC have compromised liver cirrhosis and signiﬁcant comor-
bidity, threatening their general condition and liver function
[4]. In spite of the fact that there is no evidence of a survival
beneﬁt, many advanced HCC patients in Egypt as well as in
other parts of the world with Child–Pugh B liver cirrhosis re-
ceive sorafenib monotherapy [5]. Additionally, the pathogene-
sis of HCC in Egypt is different from that of the patients
enrolled in the 2 landmark studies with HCV genotype 4 being
the predominant etiologic factor in the Egyptian population
compared to HCV genotype 2 and 3 in the European popula-
tion of SHARP study or HBV infection in the Asian paciﬁc
study [2,3]. Thus, a study of the efﬁcacy and safety of sorafenib
in an unselected Egyptian HCC population was warranted. So,
in the current study we evaluated sorafenib monotherapy in
the everyday clinical practice patient population as they pres-
ent in Egypt. Furthermore we explore the role of a number
of baseline clinicopathological parameters in treatment evalu-
ation and its association to survival outcome.
Patients and methods
Patients
Access to sorafenib was made available at Ain Shams Univer-
sity Hospitals, clinical oncology department since 2010. All pa-
tients considered for sorafenib were reviewed by a panel of
clinical oncologists. The criteria for the selection of patients
for sorafenib monotherapy were: advanced hepatocellular car-
cinoma diagnosed according to the criteria of AASLD [6], not
amendable for locoregional treatment (including transcatheter
arterial chemoembolization, radio frequency ablation (RFA),
and surgery), ECOG PS 0–2, Child Pugh A or B with no his-
tory of uncontrolled cardio- or cerebrovascular disease. All pa-
tients had a dynamic imaging study (three-phase CT scan or
MRI) performed at baseline, blood pressure assessment, bloodworkup including complete blood count, liver function tests,
coagulation studies and serum aFP.
Treatment
Sorafenib was administered at a dose of 800 mg daily. Dose
reduction and treatment delay were performed as per the semi-
nal phase 2 study of sorafenib in HCC. Treatment was contin-
ued until radiological progression, unacceptable toxicity, or
death. Patients were seen every 3 weeks for clinical assessment.
Response assessment was performed every 2 months and in-
cluded repeating the initial dynamic imaging study (CT-scan
or MRI), liver function tests, coagulation studies and serum
aFP.
Efﬁcacy and toxicity assessment
Response evaluation was performed according to RECIST cri-
teria, v.1.0 while toxicity assessment was performed according
to NCI-CTCAE v3.0 [7].
Statistical analysis
The primary end points were overall survival (OS) while sec-
ondary end points included progression free survival (PFS)
and toxicity. The analysis of objective tumor response was per-
formed according to an intention to treat analysis (ITT). The
Kaplan–Meier method was used for the survival analysis. A
Cox proportional hazard analysis of baseline clinicopatholog-
ical characteristics was performed to assess a potential associ-
ation to survival outcome and followed by a multivariate Cox
regression analysis. The level of statistical signiﬁcance was 5%.
All P values are two sided and reported with 95% conﬁdence
intervals. All statistical analyses were carried out using SPSS
v.17 software.
Results
Patient characteristics
A total of 41 patients were consecutively treated at the Depart-
ment of clinical Oncology at Ain Shams University Hospitals,
Cairo, Egypt between January 2010 and June 2011 and fol-
lowed until January 2012. Median follow-up time was
13 months, ranging from 30 to 777 days.
Table 1 shows baseline patient and disease characteristics
together with the results of the univariate survival analysis of
potential prognostic factors. 53 percent of the patients were
in PS 0–1, and 30% had a well preserved liver function (CP-
A). HCV was the primary cause of liver disease, followed by
Table 3 Adverse events during sorafenib therapy.
Adverse event Any grade Grade 3/4
Overall incidence (80%) (23%)
Dermatologic
reactions
Hand foot skin reaction (61%) (38%)
Rash/desquamation (7%) (3%)
Constitutional
symptoms(fatigue)
(26%) (3%)
Diarrhea (30%) (0%)
Liver dysfunction (11%) (7%)
Gastrointestinal
bleeding
(3%) (0%)
Peripheral
neuropathy
(3%) (0%)
Table 1 Baseline patient and disease characteristics together
with the results of the survival analysis of potential prognostic
factors.
Characteristic (%) mOS (months) 95%CI p Value
ECOG performance score
0–1 53 7.01 5.63–8.38 0.0001
2 47 3.03 2.61–3.44
Child Pugh class
A 30 12.04 0.59–23.48 0.013
B 70 5.23 3.87–6.58
Macroscopic vascular invasion
Yes 38 7.07 5.58–8.28 0.164
No 62 5.07 4.85–5.28
Extra hepatic spread
Yes 23 6.25 4.66–7.83 0.991
No 77 7.01 4.65–9.37
Table 2 Response to sorafenib treatment in patients with
advanced HCC according to the intention to treat analysis
(ITT).
Levels of response ITT (%)
Complete response 2
Partial response 11.5
Stable disease 61
Progressive disease 25.5
Figure 1 Kaplan–Meier analysis of overall survival according to
ECOG performance score.
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had highly advanced disease with macroscopic vascular inva-
sion (38%) and extrahepatic metastases (23%) (Table 2).
Treatment outcome
The median OS (mOS) for the entire cohort of patients was
6.25 months. As illustrated in Fig. 1, patients in PS 1 had a
mOS of 7.01 months, whereas patients in PS 2 had a mOS of3.03 months (p= 0.0001). CP-A patients had a mOS of
12.04 months versus 5.23 months among CP-B patients
(p= 0.013).
The median PFS (mPFS) for the entire cohort of patients
was 4.0 months, patients with PS 1 had a mPFS of 5.8 months,
whereas patients in PS 2 had a mPFS of 2.2 months
(p= 0.001). CP-A patients had a mPFS of 8.0 months versus
4.0 months among CP-B patients (p= 0.007).
Besides PS and Child–Pugh status, baseline alpha feto-
protein levels had a signiﬁcant inﬂuence on survival in the
multivariate analysis. Thirty-four percent of the patients
did not receive a full dose of sorafenib, because of dose
reduction during treatment. Discontinuation of treatment
was due to objective disease progression in 85% of patients,
while 15% stopped sorafenib therapy due to speciﬁc adverse
event. Two patients died while on treatment, all of them due
to disease progression. Three patients were still on treatment
at the end of follow up. Thirty-eight patients (92%) com-
pleted at least 12 weeks of sorafenib therapy and were evalu-
able for the assessment of tumor response according to the
deﬁnition sited above. There was one case of complete re-
sponse. Eleven percent had a partial response with substan-
tial regression of tumor lesions on the CT scan. All
responders were in PS 0–1 at baseline, and 5 of the total
7 were classiﬁed as CP-A.Toxicity
Twenty-three percent of the patients experienced grade 3–4
toxicity, with the most frequent being fatigue, diarrhea, and
hand-foot syndrome. (Table 3)Discussion
Hepatocellular carcinoma has increased in Egypt in the past
years, becoming the most common cancer among men [8]. De-
spite signiﬁcant progress with the advent of Sorafenib as a
treatment option for advanced HCC, advanced HCC is still
challenging for every practicing oncologist. In this retrospec-
tive analysis of Sorafenib-treated Egyptian HCC patients, we
found a median overall survival of only 6.25 months (Figs. 2
and 3).
Figure 2 Kaplan–Meier analysis of overall survival according to
ECOG Child–Pugh score.
Figure 3 (A) BCLC C, child A patient, 52 years, not eligible for
any loco regional treatment, started on sorafenib 800 mg per day.
(B) CT evaluation after 3 months of treatment showing stable
response disease by RECIST criteria.
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SHARP study (10.7 months), and also in the Asian-Paciﬁc
study (6.5 months) [2,3]. We found that the prognosis was
dependent on performance status, Child Pugh status in addi-
tion to baseline alpha fetoprotein. Patients with a better per-
formance and a healthier liver condition lived almost twice
as long as the less healthy subjects, but still not as long as
the patients in the landmark phase 3 sorafenib studies. This
may be explained by the difference in baseline clinicopatholog-
ical characteristics of the patients reviewed in our study com-
pared to the patients randomized in the SHARP and Asian-
Paciﬁc trials. In our study, a large percentage of our patients
were in PS 2 and child score >7. Moreover, the etiology of
underlying liver disease is different with the majority of pa-
tients in our study having post hepatitis C liver cirrhosis,
whereas only about 5% have non alcoholic steatohepatitis. Pa-
tients with HCC and an underlying hepatitis C related liver cir-
rhosis may be particularly subject to co morbidities which will
inﬂuence the tolerability of sorafenib. Therefore, one third of
the patients did not receive a full dose of sorafenib.
A more recent, prospective series of 300 patients classiﬁed
as CP-A or -B treated with sorafenib reported a median OS
for child B patients of 3.4 months, which is lower than the
survival rate we found in this study (mOS of 5.2 months
for CP-B patients) [9]. Moreover, three subjects in our study
turned out to be long-term survivors and continued treat-
ment at the end of follow up, suggesting that some patients
may derive exceptional beneﬁt from sorafenib, and one sub-
ject in our study has achieved complete response consistent
with other published case reports of complete responders
in the literature [10,11]. Therefore, reliable predictive fac-
tors-both clinical and molecular-enabling the identiﬁcation
of this subset of patients are eagerly awaited. Alpha-fetopro-
tein (aFP), a traditional tumor marker of HCC, has been
suggested previously as a marker for response to sorafenib
in HCC [12]. In agreement with other clinical studies we
found that higher baseline aFP was an independent poor
prognostic indicator [13].
As demonstrated in other reports [14], sorafenib is also tol-
erable in those with compromised liver function or PS as the
incidence and grade of adverse events were not different signif-
icantly among the patients with better versus worse perfor-mance or child score. However, the pattern of side effects is
different with higher incidence of hepatotoxicity in those with
higher baseline child score, additionally it should be noted that
child B and poor performance patients received sorafenib for a
shorter time with higher incidence for dose reduction and/or
discontinuation.
Treatment with sorafenib has been deemed cost effective
compared with best supportive care in hepatocellular carci-
noma in some developed countries, however in a developing
country like Egypt cost effectiveness and cost utility analysis
need more detailed assessment [15]. In conclusion, sorafenib
treatment is tolerable and associated with clinical beneﬁt in
Egyptian patients with advanced HCC with good performance
PS and compensated liver function. The outcome of patients
with poor performance or compromised liver function is poor,
regardless of whether they are treated or not. Therefore, in the
context of a low income country like Egypt, sorafenib treat-
ment cannot be recommended except for a highly selected sub-
group of patients with better performance and liver function.
Further molecular and clinical assessment of the distinct
pathobiological pattern of HCC in Egypt is highly recom-
mended to further elucidate the nature of disease in this area
of the world.
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